✔ COMPLIANT
★☆☆
Biotechnology & Medical Research | USA
Business: PASS
Kaleido Biosciences Inc has cleared the Business screen. Its business activity is compliant with the Shariah standard. If you find this result mistaken or questionable, let us know in the comments.
Financials: PASS
The financials pass just one standard and fail in the other two.
FTSE
| Debt/A | 35.4% | ✘ |
| Cash/A | 77.89% | ✘ |
| (AR+C)/A | 77.89% | ✘ |
AAOIFI
| Debt/MC | 30.45% | ✘ |
| Cash/MC | % |
DJIM
| Debt/24MC | 8.18% | ✔ |
| Cash/24MC | 17.99% | ✔ |
| AR/24MC | % |
Total Analysts: 6
Recommendation Rating
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Low: 6
High: 22
| Market cap | 69002847 |
| Assets | 59344000 |
| Dividends per Share | |
| Revenue Growth |
Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its Microbiome Metabolic Therapies (MMTs) is designed to drive the function and distribution of the microbiomes existing microbes in order to decrease or increase the production of metabolites to certain bacteria in the microbiome community. The Company is also advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with unmet patient needs. The Company utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates into clinical studies in healthy subjects and patients. Its KB195 is the lead MMT candidate for development in the treatment of patients with urea cycle disorders. The Company is conducting a Phase II clinical trial under an Investigational New Drug Application (IND).
| ✘ FTSE | ✘ AAOIFI | ✔ DJIM |
✔ COMPLIANT
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Responses